Successful management of primary immune thrombocytopenia with romiplostim during open heart surgery in a hemodialysis patient

DOI Web Site PubMed

Bibliographic Information

Other Title
  • 維持透析患者の開心術前後にロミプロスチムで治療した特発性血小板減少性紫斑病
  • 症例報告 維持透析患者の開心術前後にロミプロスチムで治療した特発性血小板減少性紫斑病
  • ショウレイ ホウコク イジ トウセキ カンジャ ノ カイシンジュツ ゼンゴ ニ ロミプロスチム デ チリョウ シタ トクハツセイ ケッショウバン ゲンショウセイ シハンビョウ

Search this article

Abstract

<p>A 66-year-old male undergoing maintenance hemodialysis presented with mild thrombocytopenia. He also had aortic valve stenosis and required aortic valve replacement. In addition, he required anticoagulation therapy with warfarin because of chronic subclavian artery occlusion. He was eventually diagnosed with immune thrombocytopenic purpura (ITP), although there were no bleeding tendencies. The patient was preoperatively treated with thrombopoietin receptor agonist (romiplostim®) because of the risk of bleeding complication during cardiac surgery. The platelet count rapidly increased with low-dose romiplostim, and no thrombotic complication occurred. During surgery, no significant bleeding complications were observed. This report suggests that romiplostim is a useful treatment option for the management of bleeding complication during cardiac surgery in a hemodialysis patient with ITP.</p>

Journal

  • Rinsho Ketsueki

    Rinsho Ketsueki 60 (1), 28-32, 2019

    The Japanese Society of Hematology

Related Projects

See more

Keywords

Details 詳細情報について

Report a problem

Back to top